Dyne Therapeutics (DYN) Gains from Sales and Divestitures (2020 - 2026)

Dyne Therapeutics' Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $161857.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures fell 71.36% year-over-year to $161857.0; the TTM figure through Mar 2026 stood at $161857.0 (down 71.36% YoY), while the FY2025 annual figure was $1.3 million, up 19.02% from the prior year.
• Gains from Sales and Divestitures was $161857.0 for Q1 2026 at Dyne Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q4 2025 to a low of $20504.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $496845.7 across 5 years, with a median of $386336.0 in 2023.
• The sharpest annual moves came in 2023 and 2026: Gains from Sales and Divestitures jumped 395.19% in 2023, then sank 71.36% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $289626.0 in 2022, then soared by 69.28% to $490269.0 in 2023, then surged by 118.41% to $1.1 million in 2024, then gained by 19.02% to $1.3 million in 2025, then sank by 87.3% to $161857.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $161857.0 (Q1 2026), $1.3 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.